Identifying Genetic Markers for Paclitaxel Sensitivity in Cancer Cells
Author Information
Author(s): Eng Lawson, Ibrahim-zada Irada, Jarjanazi Hamdi, Savas Sevtap, Meschian Mehran, Pritchard Kathleen I, Ozcelik Hilmi
Primary Institution: Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
Hypothesis
Can genetic variations in cancer cell lines predict sensitivity to paclitaxel?
Conclusion
The study identified 10 genetic variants associated with paclitaxel sensitivity, suggesting they could serve as biomarkers for predicting drug response.
Supporting Evidence
- 43 SNPs were significantly associated with paclitaxel response.
- 10 of these SNPs were located within protein-coding genes.
- mRNA expression analysis showed increased expression in sensitive cell lines for several identified genes.
Takeaway
Researchers found specific genes that can help predict how well cancer cells respond to a drug called paclitaxel, which is used to treat cancer.
Methodology
The study used genome-wide association analysis on SNP-genotype data from the NCI60 cancer cell line panel to identify genetic variants linked to drug response.
Potential Biases
Potential confounding by race or tumor type in the identification of pharmacogenomic markers.
Limitations
The study's findings may not fully represent in vivo responses due to the use of cell lines, and confounding factors like tumor type may affect results.
Participant Demographics
The study utilized the NCI60 panel, which includes a variety of cancer cell lines but does not specify demographic details.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website